Concurrently, Dovitinib, targeting FLT1, EGFR, FLT3 and KIT, acts as a EGFR inhibitor and FLT3 inhibitor, with previous research showing Dovitinib showed treatment efficacy in naïve and imatinib-resistant BCR::ABL(+) leukemia cells66. This evidence concerns the gene FLT1 and leukemia.